He says it's a one drug story, and there are headwinds to deal with, and "we think the news is priced into the stock."
Not a chance brother. They are totally different franchises, cant even compare.
Adam is trying to torpedo another good company named MNKD. Adam needs to be put out of the business of helping shorts to destroy small investors.
The conference call this morning was excellent and spells out the success of TRAFFIC/TRANSPORT, Verity, Third, Pappa, Glad, Harvey, and all longs;;;;;;; Congratulations for your patience and faith in this long journey, which is just starting to deliver on it's promise. VX 661 and second generation correctors will likely improve outcomes even greater for the CF community and the revenue from 809/770 will allow vertex to progress those assets plus further develop the non-CF pipeline of drugs to treat autoimmune diseases, cancer, neurologic diseases, and HIV.
I am happy for the Shareholders of VRTX and I cross posted my comments as there are a lot of Shorts on the MNKD board who are trying to scare the MNKD shareholders who are on the verge of having a day like VRTX had today. One has to look at the long term in investing and the VRTX product is one that is good for the Cystic Fibrosis Patient.
I feel the same way about the MNKD Afrezza product. But the shorts are trying to beat the Cr-p out of MNKD. Vertex today shows why its great to believe and be long in a good company.
Today you saw the market move on a drug for cystic fibrosis patient.
The market reacted vey nicely on that drug this am that only had a limited market of about 35,000 users. That drug got FDA approval Vertex VRTX up $ 34.63 a share to 101.10. Think about the market for Afrezza. Afrezza is a low cost drug that will be available to millions of users.
We are on the verge of a diabetic revolution after approval. VRTX product has a price of about $100,000 per year. That is a limited market compared to what MNKD has available worldwide. How many Patient's will the Obamacare panel allow to buy a $100,000 per year product.
Afrezza will be a cheap comodity priced drug that will be competitive with injections and not need any refrigeration. So think about the usage world wide in developing nations. This product will help Obamacare as it will keep the diabetic out of the ER when they have a serious diabetic event.
oops meant Geoffrey..here he is
Today you gonna make money and tomorrow many babies will cry, whoever followed you :)
Vrtx can only go up not even god him self can being vrtx down vrtx can only go up not even god him self can being vrtx down
Sentiment: Strong Buy